Breast cancer during pregnancy is uncommon; however, it is one of the most common malignancies affecting pregnant women. Pregnancy-associated breast cancer (PABC) is a complex entity characterized by unique risk factors, presentation, and pathology. Furthermore, although management generally aims to mirror that for nonpregnant patients, there are distinct aspects of oncologic care delivery specific to PABC. The focus is on optimizing maternal outcomes while maximizing maternal and fetal safety. A multidisciplinary approach is key, and the timing of various treatment modalities is critical. Postdelivery care and counseling are also imperative to address issues such as contraception, breastfeeding, and future fertility. In the present review, we discuss the current knowledge base and the diagnostic and treatment landscape for PABC, including recent literature and practice pattern updates.

01 Mar 2025·JCO Oncology Practice

Reimagining Deintensification for Low-Risk Breast Cancer

Review

Author: Al-Hilli, Zahraa ; Shah, Chirag ; Kruse, Megan

As outcomes for low-risk breast cancer continue to improve, research and clinical paradigms are increasingly focused on appropriate deintensification with the goal of improving the therapeutic ratio of breast cancer treatment. These deintensification approaches span across disciplines including breast surgery, radiation therapy, and systemic therapy. With regard to breast surgery, studies have continued to push deintensification when it comes to surgical margins with breast conservation, reducing re-excision rates, whereas deintensification of axillary surgery has reduced the rates of axillary lymph node dissection and increasingly the need for any axillary surgery, including sentinel lymph node biopsy for low-risk patients. With regard to radiation therapy, studies have allowed for a drastic reduction in treatment duration, whereas approaches that reduce the target of treatment have led to a change from from treatment daily for 5-7 weeks to many low-risk patients completing treatment in just five treatments. With regard to systemic therapy, use of genomic assays and tumor biology has led to reduced utilization of cytotoxic chemotherapy, with studies also allowing for dose reduction of endocrine therapy for patients with ductal carcinoma in situ. Moving forward, greater focus should be placed on interdisciplinary deintensification approaches such as the consideration of radiation therapy alone as compared with endocrine therapy alone for low-risk breast cancers.

01 Jan 2025·Practical Radiation Oncology

Comparison of Acute and Late Toxicities With Daily Versus Every-Other-Day 5-Fraction Partial Breast Radiation Therapy

Article

Author: Cherian, Sheen ; Tendulkar, Rahul ; Patel, Arya ; Amarnath, Sudha ; Spera, Connor ; Parker, Sean M ; Billena, Cole ; Al-Hilli, Zahraa ; Halima, Ahmed ; Obi, Elizabeth ; Shah, Chirag ; Moncaliano, Maria Claudia

PURPOSEPartial breast irradiation (PBI) delivered with intensity modulated radiation therapy over 5 fractions every other day represents an attractive, convenient method of delivering adjuvant radiation therapy for well-selected patients without compromising oncologic or toxicity outcomes. Condensing this regimen to a week of treatment through consecutive daily delivery may further increase patient convenience, though a comparison of toxicities between daily and every other day regimens is limited.METHODS AND MATERIALSWe retrospectively reviewed 507 patients from an institutional registry undergoing PBI for ductal carcinoma in situ (DCIS) or early-stage breast cancer (T1-2N0/x) from 2015 to 2022. All patients received 30 Gy in 5 fractions with intensity modulated radiation therapy. Acute (toxicity within 90 days of treatment) and chronic toxicity were recorded.RESULTSOf the 507 patients, 351 were treated every other day, and 159 were treated daily. Median follow-up was longer in the every-other-day group (2.4 vs 1.9 years, P < .001). With regards to acute toxicity, there was slightly reduced grade 1 to 2 dermatitis with daily treatment (39% every other day vs 35% daily, P = .06), while rates of fatigue (18% every other day vs 20% daily, P = .09) were similar. Rates of chronic toxicities were comparable between the two approaches, with no differences in the rates of chronic hyperpigmentation (14% every other day vs 14% daily, P = .97), telangiectasias (1% every other day vs 1% daily, P = .92), mild fibrosis/induration (13% every other day vs 13% daily, P = .91), and lymphedema (0% every other day vs 1% daily, P = .31).CONCLUSIONSOverall, 5-fraction PBI delivered daily appears to be well tolerated with similar acute and chronic toxicity to every other day fractionation.

100 Deals associated with Integrated Surgical Institute LLC

100 Translational Medicine associated with Integrated Surgical Institute LLC

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Jun 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Integrated Surgical Institute LLC

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Jun 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing